Acute lymphoblastic leukaemia.
Malard F, Mohty M.
Lancet. 2020 Apr 4;395(10230):1146-1162. doi: 10.1016/S0140-6736(19)33018-1.
Ponatinib and blinatumomab for Philadelphia chromosome-positive acute lymphoblastic leukaemia: a US, single-centre, single-arm, phase 2 trial.
Jabbour E, Short NJ, Jain N, Huang X, Montalban-Bravo G, Banerjee P, Rezvani K, Jiang X, Kim KH, Kanagal-Shamanna R, Khoury JD, Patel K, Kadia TM, Daver N, Chien K, Alvarado Y, Garcia-Manero G, Issa GC, Haddad FG, Kwari M, Thankachan J, Delumpa R, Macaron W, Garris R, Konopleva M, Ravandi F, Kantarjian H.
Lancet Haematol. 2023 Jan;10(1):e24-e34. doi: 10.1016/S2352-3026(22)00319-2. Epub 2022 Nov 16.
Refractory chronic lymphocytic leukemia--new therapeutic strategies.
Schnaiter A, Stilgenbauer S.
Oncotarget. 2010 Nov;1(7):472-482. doi: 10.18632/oncotarget.184.
The menin inhibitor revumenib in KMT2A-rearranged or NPM1-mutant leukaemia.
Issa GC, Aldoss I, DiPersio J, Cuglievan B, Stone R, Arellano M, Thirman MJ, Patel MR, Dickens DS, Shenoy S, Shukla N, Kantarjian H, Armstrong SA, Perner F, Perry JA, Rosen G, Bagley RG, Meyers ML, Ordentlich P, Gu Y, Kumar V, Smith S, McGeehan GM, Stein EM.
Nature. 2023 Mar;615(7954):920-924. doi: 10.1038/s41586-023-05812-3. Epub 2023 Mar 15.
Revumenib: First Approval.
Syed YY.
Drugs. 2025 Apr;85(4):577-583. doi: 10.1007/s40265-025-02161-5.
A 17-gene stemness score for rapid determination of risk in acute leukaemia.
Ng SW, Mitchell A, Kennedy JA, Chen WC, McLeod J, Ibrahimova N, Arruda A, Popescu A, Gupta V, Schimmer AD, Schuh AC, Yee KW, Bullinger L, Herold T, Görlich D, Büchner T, Hiddemann W, Berdel WE, Wörmann B, Cheok M, Preudhomme C, Dombret H, Metzeler K, Buske C, Löwenberg B, Valk PJ, Zandstra PW, Minden MD, Dick JE, Wang JC.
Nature. 2016 Dec 15;540(7633):433-437. doi: 10.1038/nature20598. Epub 2016 Dec 7.
Ferritin aggregation cell engager for CAR T avidity engineering against refractory leukemias.
Li F, Hu Y, Wang Y, Zhang X, Qiu S, Hu X, Wang W, Wang S, Guo P, Song C, Wang H, He C, Sun J, Yu D, Yi S, Wei J, Liu F, Zheng C, Wang J, Li Y, Ma G, Wei W.
Cell. 2026 Apr 2;189(7):1942-1956.e26. doi: 10.1016/j.cell.2026.02.005. Epub 2026 Mar 9.
Treatment of relapsed or refractory chronic lymphocytic leukemia.
Veliz M, Pinilla-Ibarz J.
Cancer Control. 2012 Jan;19(1):37-53. doi: 10.1177/107327481201900105.
Efficacy of ruxolitinib in the treatment of relapsed/refractory large granular lymphocytic leukaemia.
Marchand T, Pastoret C, Damaj G, Lebouvier A, Herbaux C, Moignet A, Pavlosky M, Pavlosky A, Blouet A, Eloit M, Launay V, Lebreton P, Stamatoullas A, Nilsson C, Ochmann M, Prola J, Lamy T.
Br J Haematol. 2024 Sep;205(3):915-923. doi: 10.1111/bjh.19476. Epub 2024 Apr 19.
Hairy Cell Leukaemia.
Cross M, Dearden C.
Curr Oncol Rep. 2020 Apr 16;22(5):42. doi: 10.1007/s11912-020-00911-0.
